Passage BIO, Inc.: 5%+ holders

Passage BIO, Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-09. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Purpose of Transaction (Item 4)

Orbimed Advisors LLC

The Reporting Persons from time to time intend to review their investment in the Issuer on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer's Shares in particular, as well as other developments and other investment opportunities. Based upon such review, the Reporting Persons will take such actions in the future as the Reporting Persons may deem appropriate in light of the circumstances existing from time to time. If the Reporting Persons believe that further investment in the Issuer is attractive, whether because of the market price of Shares or otherwise, they may acquire Shares or other securities of the Issuer either in the open market or in privately negotiated transactions. Similarly, depending on market and other factors, the Reporting Persons may determine to dispose of some or all of the Shares currently owned by the Reporting Persons or otherwise acquired by the Reporting Persons either in the open market or in privately negotiated transactions. Except as set forth in this Schedule 13D, the Reporting Persons have not formulated any plans or proposals which relate to or would result in: (a) the acquisition by any person of additional securities of the Issuer or the disposition of securities of the Issuer, (b) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-07-24; the filing has the rest

Lynx1 Capital Management LP

The Reporting Persons originally acquired the securities reported herein because they believe the securities are undervalued and represent an attractive investment opportunity and they continue to hold the shares of Common Stock reported herein for investment purposes. The Reporting Persons previously reported their beneficial ownership on Schedule 13G pursuant to Rule 13d-1(c) under the Act. As a result of the acquisition of additional shares of Common Stock described in Items 3 and 5(c), the Reporting Persons' aggregate beneficial ownership has equaled or exceeded 20% of the outstanding Common Stock. Accordingly, the Reporting Persons are no longer eligible to report on Schedule 13G under Rule 13d-1(c)(3) and are filing this Schedule 13D pursuant to Rule 13d-1(f)(1). On June 24, 2026, the Issuer, Peregrine Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of the Issuer ("Merger Sub"), and Remix Therapeutics, Inc., a Delaware corporation ("Remix") entered into an Agreement and Plan of Merger (the "Merger Agreement") substantially in the form attached as Exhibit 99.2 to this Schedule 13D, pursuant to which Merger Sub will merge with and into Remix, with Remix surviving the merger and becoming a wholly owned subsidiary of the Issuer (the "Merger"). Following the Merger, the combined company is expected to be renamed "Remix Therapeutics, Inc." and to trade on Nasdaq under the symbol "RMTX." In connection with the Merger, the Lynx1 Fund has agreed …The first part of Item 4 of the SCHEDULE 13D filed 2026-07-02; the filing has the rest

Timeline

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes